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Abstract
Schizophrenia is associated with cognitive deficits for which treatments remain elusive. The effects of
risperidone (an antipsychotic differing in some of its pharmacological properties from typical agents) on
cognitive deficits have not been extensively investigated. Mismatch negativity (MMN), N2 and P3 are
cognitive event-related potentials that index preattentive (MMN) and attention-dependent information
processing (N2, P3) and provide a measure of cognitive deficits in schizophrenia. The effects of risperidone
treatment on MMN, N2 and P3 generation in chronic schizophrenic patients were investigated in an open-
label, uncontrolled study. Risperidone treatment significantly reduced psychotic symptoms. It was associated
with a decrease of peak latencies, particularly pronounced for P3. However, it did not significantly affect
abnormal MMN or P3 amplitudes. The results suggest an effect of risperidone on processing speed, particularly
in attention-dependent tasks. These results are in agreement with findings in recent studies on the cognitive
effects of risperidone.
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Introduction
Cognitive deficits are amajor aspect and cause of disability
in schizophrenia (Green, 1996), but effective pharma-
cological treatments have remained elusive. Several
neuropsychological studies have reported significant
effects of clozapine, risperidone and olanzapine on
cognitive functioning (Green et al., 1997 ; Hagger et al.,
1993 ; Hoff et al., 1996 ; McGurk and Meltzer, 1997 ; Stip
and Lussier, 1996) , although other studies have failed to
find such effects (Goldberg et al., 1993 ; Zahn et al., 1994).
Event-related potentials (ERPs) provide an objective
index of cognitive dysfunction in schizophrenia, and a
reliable method for assessing effects of medication on
underlying brain activity. Upon presentation of auditory
stimuli a negative potential peaking at approx. 100 ms,
hence termed N100 or N1, followed by a positive wave
with a peak latency of approx. 200 ms, called P200 or P2,
are observed in an obligatory fashion. N1 and P2 are
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considered sensory or exogenous ERPs since their specific
characteristics depend primarily on the physical features
of the stimuli. If in a series of repeatedly presented
standards a stimulus deviating in any physical charac-
teristic (the so-called ‘oddball ’ stimulus) is presented,
additional ERP components termed mismatch negativity
(MMN), N2 and P3 can be recorded. MMN is an early
cognitive potential, occurring with a latency of approx.
100–200 ms and manifests an attention-independent
process comparing the deviant stimulus to the sensory
memory trace of the standard stimulus (Na$ a$ ta$ nen, 1990 ;
Novak et al., 1990). MMN thus indexes the operation of
a simple form of auditory working memory called echoic
memory. In contrast, N2, a negative deflection occurring
fronto-centrally with a latency of approx. 200 ms, and P3,
a positive wave with an peak latency of approx. 300 ms,
are attention-dependent potentials that are only observed
if a specific behaviour is required upon detection of
the ‘oddball ’ or target stimulus. N2 is thought to reflect
stimulus categorization (Ritter et al., 1979, 1983), whereas
P3 is believed to reflect allocation of attention and
activation of immediate memory (Johnson, 1986 ; Polich
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sequence of potentials that index different stages (pre-
attentive and attention-dependent) in the processing of
behaviourally relevant target stimuli (Novak et al., 1990).
ERP studies in schizophrenia have demonstrated ab-
normalities in the generation of MMN, N2 and P3 (Catts,
1995 ; Javitt et al., 1995 ; O’Donnell et al., 1993 ; Pritchard,
1986) indicating the presence of abnormal information
processing even at the stage of the primary and secondary
auditory cortex. In addition, several studies have also
found increased latency of the P3 response in schizo-
phrenia suggesting slower processing speed (Blackwood
et al., 1987 ; Pfefferbaum et al., 1989).
Conventional antipsychotics fail to normalize abnormal
amplitudes of MMN, N2 and P3, whereas they have been
found to decrease P3 latency (Blackwood et al., 1987 ;
Ford et al., 1994). In contrast, clozapine treatment is
associated with an increase of deficient P3 amplitudes ;
however, it does not alter deficient generation of MMN
(Schall et al., 1995 ; Umbricht et al., 1998). Thus, clozapine
appears to improve attention-dependent steps in informa-
tion processing without affecting deficits in early atten-
tion-independent auditory processing.
The present investigation explores the effects of
risperidone, as a putative atypical antipsychotic, on
cognitive dysfunction in schizophrenia as assessed by
auditory ERPs using an uncontrolled study design. It is an
initial attempt at answering the question whether risperi-
done exhibits effects on auditory ERPs that are similar to
those of clozapine or more like those of conventional
antipsychotics.
Subjects and methods
This study was conducted at the Hillside Hospital of the
Long Island Jewish Medical Center (Glen Oaks, USA)
with the necessary approval by the Ethics Committee
(Internal Review Board). All subjects gave written in-
formed consent to participate in this study. Ten chronic
right-handed schizophrenic patients (M}F, 6}4 ; age,
33.3³8.7 yr) were recruited from the in- and outpatient
services of Hillside Hospital. Diagnosis was established
according to criteria of DSM-III-R (American Psychiatric
Association, 1987) by the primary investigator (D.U.) or
by a trained nurse clinician using data obtained from
patient interviews and chart reviews.
Auditory ERPs were recorded before initiation of
risperidone treatment (baseline) and after 6 wk (6 patients)
or 9 wk (4 patients) of treatment with risperidone,
respectively. In order to assess the extent of ERP
abnormalities in patients at baseline ERPs were recorded
once in 12 age-matched right-handed normal controls
(M}F, 10}1; age, 32.1³5.2 yr).
At baseline 6 patients were treated with high potency
conventional antipsychotics (3 patients with daily flu-
phenazine doses of 20, 20 and 10 mg, respectively ; 3
patients with daily haloperidol doses of 5, 10 and 20 mg,
respectively). Four patients had not been taking neuro-
leptics secondary to non-compliance with a prior treat-
ment regimen for an unknown duration and were off
neuroleptics at baseline. In addition 4 patients each
received anticholinergic and benzodiazepines at baseline.
After the recording of baseline ERPs risperidone
treatment was started and all other antipsychotic medi-
cation discontinued. Two patients received risperidone
clinically, 2 patients in the context of a double-blind
treatment study and 6 patients in the context of double-
blind study comparing once daily to twice daily dosing of
risperidone. At the time of the follow-up ERP recording
all patients received 6 mg}d of risperidone. With the
exception of 1 patient who received additional anti-
cholinergic medication none of the patients was treated
with concomitant psychotropic medication at follow-up.
Symptomatology was assessed with the Brief Psy-
chiatric Rating Scale (BPRS, anchored version ; Woerner et
al., 1988) in 2 patients and the Positive and Negative
Syndrome Scale (PANSS ; Kay et al., 1987) in the
remainder. Due to the small study sample only the BPRS
total score and BPRS psychosis factor and anergia scores
(derived from PANSS scores in 8 patients) were used for
analysis. Writing preference was used to assess handed-
ness.
EEGs were recorded with a Neuroscan acquisition
system and a Metrabyte EEG amplifier (bandpass
0.1–30 Hz) using a 16-electrode montage according to
the 10}20 International System and stored with stimulus
tags on-line on computer hard disk for further analyses.
Electrodes were placed at F3, Fz, F4, left mastoid (Lm), T3,
C3, Cz, C4, T4, right mastoid (Rm), T5, P3, Pz, P4, T6 and
above the left outer canthus for monitoring of blinks and
eye movements. An electrode placed on the nose served
as reference. ERPs were acquired during active and passive
auditory‘oddball ’ paradigms. In both conditions standard
stimuli were 1000 Hz tones, deviants were tones of
1200 Hz with a probability of 0.15, randomly presented.
Stimuli were of 50 ms duration with 5 ms rise}fall time, of
85 dB SPL (sound pressure level) and delivered binaurally
via headphones. ISI varied randomly between 700 and
800 ms. The active paradigm always preceded the passive
paradigm and consisted of two blocks with 80 deviants
each. A button press within 200–1000 ms post-stimulus
was considered a correct response. In the passive paradigm
four blocks with 110 deviants each were presented.
Subjects were watching a silent movie and told to ignore
the tones.
Averages of 1024 ms with a 100 ms prestimulus
baseline were constructed off-line, baseline-corrected and
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Table 1. Active and passive conditions of baseline and normal controls after
risperidone treatment
Normal Patients (n¯ 10)
controls
Peak Electron (n¯ 12) Baseline Follow-up
Passive condition
N1 Fz Amplitude ®1.6³1.19 ®0.9³1.1 ®0.5³0.9
Latency 96³10 86³22 79³19
P2 Fz Amplitude 1.8³1.4 2.0³1.3 3.0³1.2
Latency 175³25 164³12 159³7
MMN Fz Amplitude ®2.9³1.1* ®1.8³1.0 ®2.4³2.3
Latency 173³39* 123³19 116³16
Active condition
N1 Fz Amplitude ®2.4³1.2 ®1.5³1.6 ®1.2³0.8
Latency 105³13 93³26 87³11
P2 Fz Amplitude 2.3³2.1 1.6³0.7 1.5³1.5
Latency 218³29* 193³25 168³14‡
N2 Fz Amplitude ®4.2³3.6 ®2.4³4.2 ®1.4³4.2
Latency 139³34 150³42 157³42
P3 Pz Amplitude 12.7³5.7* 7.8³2.8 6.1³5.3
Latency 258³24† 325³61 271³47‡
Amplitudes in µV, latencies in ms.
* Normal controls vs. patients at baseline, t test : p! 0.05.
† Normal controls vs. patients at baseline, t test : p! 0.01.
‡ Patients at baseline vs. patients at follow-up, paired t test : p! 0.05.
Averages to standard and deviant stimuli in the passive
condition were rereferenced to a mathematically com-
puted average mastoid derivation for the purpose of peak
measurements. In the active paradigm only sweeps
associated with correct responses were included in the
ERP to deviant stimuli.
In both active and passive paradigm N1 and P2 were
determined from waveforms to standard stimuli at
electrode Fz within a latency window of 50–150 ms post-
stimulus for N1 and a latency window of 150–250 ms
post-stimulus for P2. MMN latency and amplitude were
determined at electrode Fz from the difference wave (ERP
to deviants minus ERPs to standards) in the passive
paradigm within a latency window of 100–225 ms post-
stimulus. N2 was measured in the difference wave (ERP to
deviant stimulus minus ERP to standard stimulus) of the
active paradigm within a latency window of 100–250 ms
post-stimulus. P3 was determined from the ERP to the
deviant stimulus in the active paradigm within a latency
window of 225–550 ms post-stimulus.
In both the passive and the active paradigm the
required minimum of sweeps surviving artifact rejection
(MMN¯ 100 ; N2 and P3¯ 25) was not reached in 1
patient each. For both paradigms ERPs were therefore
available for analyses in 9 patients.
Comparisons of latencies and peak amplitudes of the
six ERP components between normal controls and
patients were done with the help of unpaired t tests. To
restrict the number of comparisons the effects of ris-
peridone treatment on latencies and peak amplitudes of
the various ERP components were evaluated with the
help of repeated-measure ANOVAS with peak type (e.g.
N1, P2, MMN) and session (baseline, follow-up) as within-
subject factors. Analyses were done separately for the
passive and active paradigm. Post-hoc paired t tests were
used to further assess significant results. For the purpose
of evaluating differences in P3 topography between
controls and patients at baseline and effects of risperidone
treatment on P3 topography, respectively, analyses were
restricted to the 3 midline electrodes Fz, Cz and Pz and the
lateralized electrodes T3}T4 and T5}T6. For all analyses
α was set at 0.05, two-tailed.
Results
Passive paradigm (Table 1)
Comparison of patients at baseline and normal controls
Amplitudes and latencies of N1 and P2 did not differ
between patients and normal controls. However, MMN
amplitude was significantly smaller (t¯ 2.31, d.f.¯ 19, p
! 0.05) and MMN latency significantly shorter (t¯
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Effects of risperidone treatment
The peak latencies of all three ERP components were
shorter at follow-up than at baseline. A repeated-measure
ANOVA of peak latency with peak type (N1, P2, MMN)
and session (baseline, follow-up) as repeated measures
showed an effect of session that was just above the
significance level [F(1,8)¯ 4.66 ; p¯ 0.06], but not
session¬peak interaction. None of the latency changes
were significant when assessed individually with the help
of paired t tests.
Risperidone treatment was associated with a decrease
of N1 amplitude and an increase of both P2 and MMN
peak amplitudes. However, there was no significant effect
of session or a significant peak¬session interaction in a
repeated-measure ANOVA.
Active paradigm (Table 1)
Comparison of patients at baseline and normal controls
Patients showed smaller amplitudes of all four ERP
components than controls. However, only the difference
in P3 amplitude reached statistical significance (t¯ 2.34,
d.f.¯ 19, p! 0.05). In addition, peak latency of P2 was
significantly shorter (t¯ –2.1, d.f.¯ 19, p! 0.05) and
P3 latency significantly longer (t¯ 3.50, d.f.¯ 19, p!
0.01) in patients than normal controls.
Comparison of P3 topography between patients and
normal controls with the help of a repeated-measure
ANOVA (electrodes as within-subject factor ; group as
between-subject factor) showed a significant group effect,
but no group¬electrode interaction [repeated-measure
ANOVA, main effect of group : F(1,19)¯ 7.04, p! 0.02 ;
group¬electrode interaction : F(6,14)¯ 1.03, p¯ ns].
Effects of risperidone treatment
With the exception of N2 latency peak latencies were
shorter at follow-up than at baseline. A repeated-measure
ANOVA of peak latency with peak type (N1, P2, N2, P3)
and session (baseline, follow-up) as repeated measures
demonstrated a significant effect of session [F(1,8)¯ 5.74 ;
p! 0.05], but not session¬peak interaction. Paired t
tests showed that latencies of P2 and P3 were significantly
shorter at follow-up than at baseline (P2 : t¯ 2.44, d.f.¯
8, p! 0.05 ; P3 : t¯ 2.73, d.f.¯ 8, p! 0.05). At follow-
up P3 latency no longer differed significantly between
patients and normal controls (t¯ 0.8, d.f.¯ 11.2, p¯
ns).
At follow-up the peak amplitudes of all four ERP
components were smaller than at baseline. A repeated-
measure ANOVA of peak amplitude with peak type (N1,
P2, N2, P3) and session (baseline, follow-up) as repeated
Table 2. BPRS scores after risperidone treatment
Psychopathology
Baseline Follow-up
BPRS total score 51.3³8.0 43.2³8.9*
BPRS Psychosis factor score 17.2³3.2 14.5³2.8†





Figure 1. Grand averages of (a) Mismatch Negativity and
(b) P3 in normal controls (–––), patients at baseline (——)
and patients at follow-up (±±±±±±).
measures did not reveal any significant effects or inter-
actions. Finally, treatment with risperidone was not
associated with any significant effect on P3 topography as
evaluated by a repeated-measure ANOVA with electrode
sites and session as within-subject factors [main effect of
session : F(1,8)¯ 1.18, p¯ ns ; session¬electrode in-
teraction : F(3,6)¯ 0.79, p¯ ns].
Psychopathology
Treatment with risperidone was associated with signif-
icant decreases of BPRS total score and BPRS psychosis
factor score, but had no significant effect on BPRS anergia






/ijnp/article/2/4/299/756603 by guest on 05 February 2021
303Effects of risperidone on ERPs
were not significantly correlated with changes in symp-
tomatology.
Discussion
This study explored effects of risperidone treatment on
neurocognitive deficits by investigating its effects on
auditory ERPs in a small sample of chronic schizophrenic
patients. Consistent with results of previous studies we
found that patients, in comparison with age-matched
controls, showed deficient generation of MMN and P3
and increased latency of P3. Risperidone treatment was
associated with a shortening of peak latencies which was
most pronounced in the attend condition. In particular,
risperidone treatment was associated with a significant
shortening of P3 latency. In contrast, risperidone treat-
ment did not have an appreciable effect on deficient
amplitudes of MMN and P3.
The shortening of peak latencies suggests an general
enhancement of information processing speed by risperi-
done both at the preattentive and attention-dependent
level. The most pronounced effect concerned a shortening
of the latency of P300. In so far as P300 reflects operations
such as allocation of attentional resources and updating of
immediate memory (Johnson, 1986) the shortening of
P300 latency associated with risperidone treatment would
suggest that risperidone enhances the speed by which
they are carried out. Interestingly, risperidone has been
found to significantly increase reaction time compared to
haloperidol (Kern et al., 1998) and in uncontrolled studies
(Stip and Lussier, 1996) Although P3 latency and reaction
time are manifestations of different processes they are
usually highly correlated. Thus, findings concerning the
relevance of abnormal reaction time may also apply to P3
latency. In cross-sectional studies reaction time has been
found to predict short- and long-term outcome (Cancro et
al., 1971 ; Zahn and Carpenter, 1978). It is thus conceivable
that sustained effects on processing speed as indicated by
decreased reaction time and normalized P3 latency may
translate into clinically significant improvements in long-
term treatment.
In recent studies we and others have demonstrated that
clozapine treatment was accompanied by an increase of
P3 amplitude, but did not reverse deficits in MMN
generation (Schall et al., 1995 ; Umbricht et al., 1998),
suggesting that clozapine improves attention-dependent
function without affective preattentive processing. In the
present study risperidone had a significant effect on
latencies of P2 and P3, but did not affect P3 amplitude. To
the extent that these studies can be compared to the
present investigation, the results of this study would
suggest that risperidone does not share the specific effects
of clozapine, but may particularly improve speed of
information processing – an effect not observed during
clozapine treatment (Umbricht et al., 1998 ; Zahn et al.,
1994).
Several, although not all neuropsychological studies
have reported significant effects of clozapine, risperidone
and olanzapine on cognitive functioning (Goldberg et al.,
1993 ; Green et al., 1997 ; Hagger et al., 1993 ; Hoff et al.,
1996 ; McGurk and Meltzer, 1998 ; Stip and Lussier, 1996 ;
Zahn et al., 1994). To the extent that neurocognitive
improvement occurs during treatment with atypical
antipsychotics, electrophysiological studies will be im-
portant in analysing mechanisms underlying such effects.
Our previous study on clozapine suggested a particular
effect on attention-dependent information processing,
while the present study indicates that risperidone im-
proves processing speed.
In interpreting the results of this study several caveats
have to be observed. Most importantly, the number of
subjects investigated is small, considerably reducing the
power of the study to detect small effects of risperidone
and inflating the potential for type II errors. Secondly, due
to the uncontrolled design of this study alternative
explanations for the observed effects cannot be ruled out.
In particular, the decrease in latency could simply be the
result of withdrawal of conventional antipsychotics or of
unspecific treatment effects. However, what mitigates
against the former possibility are the results of previous
studies demonstrating that treatment with conventional
antipsychotics is associated with a shortening of P3
latency (Blackwood et al., 1987 ; Ford et al., 1994). The
question to what extent the effects of risperidone
observed in this study are thus comparable to, or exceed
those of, conventional antipsychotics cannot be answered
by this uncontrolled study.
This study is the first to investigate the effects of
risperidone on neurophysiological abnormalities in schizo-
phrenia ; however, it is limited by its open and un-
controlled design, its small sample size and by the fact
that not all patients could be studied in a medication-free
condition at baseline. Thus, the conclusions drawn from
the results must be seen as preliminary. Controlled studies
in larger samples are required to answer the important
issue : ‘Do newer antipsychotics improve neurocognitive
deficits in schizophrenia ? ’
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